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USE OF FREE HEMOGLOBIN AND ITS 
SURROGATE MARKERS TO DETECT AND 
MONITOR PULMONARY HYPERTENSION 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
[0001] This application is entitled to the benefit of, and 
claims priority to provisional U.S. Patent Application Ser. 
No. 60/549,629, filed on Mar. 3, 2004, which is incorporated 
herein by reference in its entirety. 
BACKGROUND OF THE PRESENT 
INVENTION 
[0002] 1. Field of the Present Invention 
[0003] The present invention relates generally to diagnos-
ing and monitoring pulmonary hypertension, and, in par-
ticular, to the use of free hemoglobin, as well as surrogates 
for free hemoglobin, as markers for detecting and monitor-
ing pulmonary hypertension. 
[0004] 2. Background 
[0005] Pulmonary hypertension contributes to the severity 
and progression of several disease states, including throm-
botic embolism to the lung, sickle cell disease, acute fat 
embolism syndrome, tumor embolism syndrome, pulmonary 
schistomasiasis, right-sided congestive heart failure and 
primary pulmonary hypertension. Patients with any of these 
conditions complicated by pulmonary hypertension are far 
more likely to be disabled or die compared with patients who 
do not have pulmonary hypertension. 
[0006] Several treatments aimed at reducing pulmonary 
hypertension once it is diagnosed are available; however, 
current methods of detecting and monitoring pulmonary 
hypertension have significant disadvantages. One such diag-
nostic method includes inserting a pulmonary arterial cath-
eter through a large vein in the neck or chest. Potential 
adverse side effects of this procedure include sustaining a 
punctured lung, incurring damage to blood vessels or the 
heart or experiencing an abnormal heart rhythm. This pro-
cedure requires expensive equipment and special compe-
tence to perform and interpret the results. 
[0007] Another method, transthoracic or transesophageal 
Doppler-echocardiography, represents a non-invasive option 
to pulmonary artery catheterization. The Doppler method 
measures the velocity of blood flow that travels in the 
reverse direction across the tricuspid valve of the heart. This 
method has the drawbacks of requiring specialized Doppler 
equipment to perform the measurement, a skilled operator to 
acquire the data, and a specialist physician to interpret the 
results. An additional disadvantage is that the mathematical 
equation used to predict the pulmonary arterial systolic 
pressure requires the value of the right atrial pressure to be 
assumed, thus introducing uncertainty into the analysis. 
[0008] Accordingly, it would be advantageous to have a 
noninvasive test or set of tests to detect and monitor the 
presence of pulmonary hypertension. 
SUMMARY OF THE PRESENT INVENTION 
[0009] The present invention comprises various methods 
of diagnosing, detecting, assessing and monitoring pulmo-
nary hypertension and various other conditions in mamma-
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lian subjects using at least one of haptoglobin, prehaptoglo-
bin, free hemoglobin, biliverdin, bilirubin, nitric oxide, 
carbon monoxide or the ratio of carbon dioxide to oxygen as 
a marker. 
[0010] Broadly defined, the present invention according to 
one aspect is a method of detecting and monitoring the 
presence of acute or chronic pulmonary hypertension, 
including collecting a bodily fluid and measuring the con-
centration of haptoglobin or its precursor, prehaptoglobin, in 
the bodily fluid. 
[0011] The present invention, according to another aspect 
of the invention is a method of detecting and monitoring the 
presence of acute or chronic pulmonary hypertension, 
including collecting a bodily fluid and measuring the con-
centration of free hemoglobin in the bodily fluid. 
[0012] The present invention, according to another aspect 
of the invention is a method of detecting and monitoring the 
presence of acute or chronic pulmonary hypertension, 
including collecting a bodily fluid and measuring the con-
centration of a product of heme catabolism in the bodily 
fluid. 
[0013] In features of this aspect, the product of heme 
catabolism may be biliverdin or bilirubin. 
[0014] The present invention, according to another aspect 
of the invention is a method of detecting and monitoring the 
presence of acute or chronic pulmonary hypertension, 
including collecting expired breath from a patient and mea-
suring the concentration of nitric oxide and carbon monox-
ide in the expired breath. 
[0015] The present invention, according to another aspect 
of the invention is a method of detecting and monitoring the 
presence of acute or chronic pulmonary hypertension, 
including collecting expired breath from a patient and mea-
suring the concentration of carbon dioxide to oxygen in the 
expired breath. 
[0016] Further areas of applicability of the present inven-
tion will become apparent from the detailed description 
provided hereinafter. It should be understood that the 
detailed description and specific examples, while indicating 
the preferred embodiment of the invention, are intended for 
purposes of illustration only and are not intended to limit the 
scope of the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
[0017] The present invention will become more fully 
understood from the detailed description and the accompa-
nying drawing, wherein: 
[0018] FIG. 1 is a graphical representation of a relation-
ship between pulmonary hypertension and free hemoglobin 
and its surrogate markers. 
[0019] FIG. 2 is a graphical representation of the results 
of the ELISA assay analysis of Example 2. 
[0020] FIG. 3 is a graphical representation of the partial 
pressure of C02 versus partial pressure of 0 2 for 178 
patients using the mean values of the first two deep exhaled 
breaths in Example 3. 
[0021] FIG. 4 is a graphical representation of the partial 
pressure of C02 versus partial pressure of 0 2 for 178 
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patients using the mean end-tidal partial pressure of C02 and 
partial pressure of 0 2 obtained during the first minute of tidal 
breathing in Example 3. 
DETAILED DESCRIPTION OF IBE 
PREFERRED EMBODIMENTS 
[0022] The following description of the preferred embodi-
ment(s) is merely exemplary in nature and is in no way 
intended to limit the invention, its application, or uses. 
[0023] Pulmonary hypertension may be defined as a con-
dition of increased mean pulmonary artery pressure over that 
which is normal and healthy for a particular person. Spe-
cifically, it may be defined as a mean pulmonary artery 
pressure greater than 25 mm Hg at rest or greater than 30 
mm Hg during exercise, with increased pulmonary vascular 
resistance. However, for some, pulmonary hypertension, and 
more particularly the adverse effects thereof, may not be 
experienced until they have a mean pulmonary artery pres-
sure greater than 40 mm Hg or higher at rest. The diagnosis 
should be made with a clinical assessment of multiple 
factors including, but not limited to, hemodynamic param-
eters, medical history and histological findings. 
[0024] Pulmonary hypertension may be generally catego-
rized as either precapillary, with changes limited to the 
arterial side of the pulmonary circulation, or postcapillary, 
with primary findings located within the pulmonary venous 
circulation, between the capillary bed and the left atrium. 
The arterial side has blood that has been oxygenated in the 
lungs and is being carried to the tissues of the body. The 
venous circulation has blood that has already passed through 
the capillaries and given up oxygen for the tissues and 
become charged with carbon dioxide and ready to pass 
through the respiratory organs to release its carbon dioxide 
and renew its oxygen supply. 
[0025] FIG. 1 is a diagram graphically representing a 
relationship between pulmonary hypertension and free 
hemoglobin and its surrogate markers. Precapillary pulmo-
nary occlusion causes an increase in shear forces on red 
blood cells as they travel through the pulmonary capillary 
bed under higher than normal driving pressure, and is thus 
likely to cause turbulent or non-laminar blood flow. Precap-
illary pulmonary occlusion may cause tricuspid regurgita-
tion, which is a disorder involving backward flow of blood 
across the tricuspid valve that separates the right ventricle 
(lower heart chamber) from the right atrium (upper heart 
chamber) and is a well-known consequence of pulmonary 
hypertension. This turbulence may cause shear forces to be 
imparted to red blood cells, leading to intracardiac hemoly-
sis. Moreover, intrapulmonary vascular occlusion with asso-
ciated pulmonary hypertension also contributes to increased 
intravascular shear forces and hemolysis in the lung vascu-
lature (step 1). Accordingly, hemolysis can occur as a 
consequence of pulmonary hypertension. The term 
"hemolysis," as used in the context of the present invention, 
refers to the destruction or dissolution of red blood cells 
(step 2), with release of hemoglobin as free hemoglobin 
(step 3). The term "hemoglobin," as used in the context of 
the present invention, refers to the red respiratory protein of 
red blood cells that transports oxygen from the lungs to the 
tissues of the body and is composed of approximately 6% 
heme and 94% globin. Heme oxygenase enzyme that is 
present in various cells of the lung and other organs catabo-
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lizes heme to biliverdin, carbon monoxide (CO) and iron 
(step 4). The term "heme oxygenase enzyme," in the context 
of the present invention, refers to an enzyme that is respon-
sible for catabolism of the heme group. The term "catabo-
lism," in the context of the present invention, refers to the 
breakdown of complex substances into more simple ones 
with release of energy. 
[0026] In a study to measure the effect of elevated pul-
monary pressure in rats, which is discussed in greater detail 
hereinbelow, a 40-fold increase in expression of messenger 
RNA coding for the heme oxygenase enzyme was observed 
in rats with elevated pulmonary pressure. Messenger RNA 
mediates the transfer of genetic information from a cell 
nucleus to ribosomes in the cell cytoplasm, where it serves 
as a template for protein synthesis. Therefore, an increase in 
expression of messenger RNA coding for heme oxygenase 
enzyme indicates that more heme oxygenase enzyme was 
being synthesized to accommodate the increase in hemolysis 
in rats with elevated pulmonary pressure. 
[0027] Once the heme group is broken down by the heme 
oxygenase enzyme, biliverdin is converted to bilirubin (step 
5). Free hemoglobin, biliverdin, bilirubin and/or carbon 
monoxide (CO) may be detected in bodily fluids and/or 
expired breath samples (step 10). Accordingly, measuring 
the concentration of free hemoglobin, biliverdin, bilirubin 
and/or carbon monoxide in a patient's bodily fluids and/or 
exhaled breath may provide a way to indicate an elevated 
hemolysis rate and therefore, vascular occlusion and pul-
monary hypertension. 
[0028] It is well known that haptoglobin decreases as a 
consequence of the release of free hemoglobin with hemoly-
sis (step 6). The term "haptoglobin," as used in the context 
of the present invention, refers to a plasma protein that is a 
normal constituent of blood serum and functions to bind free 
hemoglobin, thereby retaining iron, in the bloodstream. 
Using the above-described model, it was discovered that the 
protein haptoglobin, and its precursor proteins, prehaptoglo-
bin, were markedly decreased in the presence of the pulmo-
nary vascular occlusions that caused the right ventricular 
pressure to exceed normal pressure. The haptoglobin con-
centration decreased in proportion to the magnitude of 
pulmonary hypertension in the dimensions of both time and 
pressure; i.e., higher pulmonary arterial pressures corre-
sponded to lower haptoglobin levels. Further, elevated pul-
monary arterial pressure for a longer period of time also 
appeared to correspond to lower haptoglobin levels; i.e., the 
longer the pulmonary arterial pressure was elevated, the 
more depressed haptoglobin levels appeared. Accordingly, 
measuring the concentration of a patient's haptoglobin may 
provide a way to indicate an elevated hemolysis rate and 
therefore, vascular occlusion and pulmonary hypertension 
(step 10). 
[0029] An advantage of measuring haptoglobin in a 
patient's bodily fluid is that the concentration of haptoglo-
bin, unlike the concentration of free hemoglobin, in sampled 
bodily fluid, specifically blood, is not spuriously elevated by 
sampling procedure. A common technical difficulty with 
drawing blood, especially from sick patients, which are 
prone to hypertension, is iatrogenic hemolysis. Iatrogenic 
hemolysis is hemolysis of the blood being sampled as it is 
aspirated into the blood tube due to the small diameter of the 
needle being used to draw the blood. Iatrogenic hemolysis 
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causes the free hemoglobin to be spuriously elevated in the 
sample, therefore resulting in a false positive test. In con-
trast, haptoglobin concentration in the sampled blood does 
not go down from iatrogenic hemolysis. 
[0030] It is well known that free hemoglobin binds nitric 
oxide. Further, nitric oxide (NO) and its thiol derivative 
(SNO) are well established mediators of pulmonary vascular 
dilation. As such, removal of NO or SNO from the pulmo-
nary vascular bed may result in vasoconstriction. When 
hemolysis occurs, the heme portion of free hemoglobin 
binds NO and/or SNO (step 7), thereby causing vasocon-
striction. Pulmonary vasoconstriction causes an increase in 
pulmonary vascular resistance, and as a consequence, causes 
an increase in pulmonary arterial resistance and pulmonary 
hypertension (step 10). 
[0031] In theory, hemolysis can cause, perpetuate, and 
worsen pulmonary hypertension. Accordingly, it can be seen 
that pulmonary hypertension produces a vicious cycle of 
intracardiac and intrapulmonary hemolysis, followed by 
release of free hemoglobin, then reduction in NO and SNO, 
which causes worsened intrapulmonary vasospasm, which 
then worsens pulmonary hypertension. Pulmonary arterial 
vasoconstriction can, in turn, alter the ability of the lung to 
exchange carbon dioxide and oxygen. 
[0032] Further, it is disclosed in an article entitled "Nitric 
oxide inhalation increases alveolar gas exchange by decreas-
ing deadspace volume,"Crit. Care Med 29 (6):1195-1200, 
2001 ), that the ability to measure the apparent alveolar 
deadspace volume can be a surrogate measurement to moni-
tor the effect of nitric oxide therapy. More specifically, the 
article reports that inhaled nitric oxide causes a decrease in 
alveolar deadspace volume and alveolar partial pressure of 
carbon dioxide. As such, the article shows that alveolar 
deadspace volume is directly and linearly related to arterial-
to-end tidal co2 partial pressure. These findings suggest that 
nitric oxide therapy can thereby increase alveolar gas 
exchange in injured lungs. Conversely, a measurement of the 
alveolar deadspace volume may be used as a means to 
monitor for the adverse effect of the withdrawal of nitric 
oxide from the lung vasculature, as in the case of increased 
free hemoglobin (step 8). 
[0033] U.S. Pat. No. 6,575,918 to Kline, (the '"918 
patent"), the entirety of which is herein incorporated by 
reference, discloses a way in which to measure alveolar 
deadspace volume. More particularly, the '918 patent dis-
closes that the expired ratio of carbon dioxide ( C02) to 
oxygen (02) and the plot of the C02 as a function of the 0 2 
can be used to detect the presence of pulmonary hyperten-
sion associated with increased alveolar deadspace (step 9). 
Higher levels of pulmonary hypertension correspond to 
higher apparent alveolar deadspace, manifested as a lower 
ratio of expired C02 to 0 2 (step 10). 
[0034] More specifically, pulmonary arterial thromboem-
bolism, or severe vasoconstriction, impedes blood flow to 
alveoli, producing lung units with very high ratios of ven-
tilation to perfusion. Thus, the experimental diagram of 
alveolar partial pressure of carbon dioxide (P c02), plotted as 
a function of alveolar partial pressure of oxygen (P 02), 
predicts a low ratio of these gases (P co2/P 02) in the alveolar 
compartment of patients with pulmonary vascular occlusion. 
[0035] In an attempt to develop noninvasive methods to 
detect and monitor pulmonary hypertension, an experimen-
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tal model of pulmonary hypertension has been employed. A 
detailed description of the model may be found in a previ-
ously published article entitled "Chemokines Accumulate in 
the Lungs of Rats with Severe Pulmonary Embolism 
Induced by Polystyrene Microspheres,"J. Immunol 
171:5529-5536, 2003. Briefly summarized, in this model, 
plastic microspheres or beads of known diameter are infused 
into a rat's venous circulation. These beads are impervious 
and lodge into the rat's pulmonary arteries creating an 
occlusion. The term "occlusion" as used herein refers to an 
obstruction or closure of a passageway or vessel. By titrating 
the dose of the beads, the model can be used to produce 
pulmonary hypertension in the rats and to vary the severity 
and time course of development of pulmonary hypertension. 
[0036] This experimental model has clinical relevance for 
humans because it produces precapillary occlusion and 
manifests gas exchange abnormalities, pleural effusion and 
pulmonary hypertension as is seen in humans with large 
pulmonary embolism. The term "pleural effusion," as used 
in the present invention, refers to an exudation of fluid from 
the blood or lymph into a space located between the lung and 
the chest wall. 
[0037] Generally, it is thought that as the severity of 
pulmonary embolism increases, the occurrence and severity 
of pulmonary hypertension also increases. Further, with 
pulmonary embolism, the mechanical vascular occlusion 
and the additional release of vasoconstrictive agents from 
the intrapulmonary thrombus, such agents including seroto-
nin, prostanoids PGF2a, thromboxanes A and B, leukot-
rienes C4, D4 and E4, platelet activating factor and others, 
appear to produce a synergistic effect that causes acute 
pulmonary hypertension, worsened gas exchange and 
impaired right ventricular function. 
[0038] Additionally, using the above-described experi-
mental model, evidence of precapillary pulmonary vasocon-
striction associated with pulmonary embolism has been 
shown, including visual evidence in the form of cineangio-
grams and physiological evidence in the form of gas 
exchange measurements, has been shown. The term "vaso-
constriction," as used in the context of the present invention, 
refers to constriction of a blood vessel. 
[0039] In brief summary, it was shown that the induction 
of pulmonary embolism causes a reduction in the ratio of 
CO to 0 2 in expired breath and that such ratio increases with 
trea
2
tment effect, which is coincident with improved lung 
perfusion. In addition, direct pulmonary angiography was 
performed on the rats with cineangiographic analysis of 
pulmonary vascular perfusion to determine how the rats 
responded to treatment. The term "cineangiography," as 
used in the present invention refers to the use of a movie 
camera to film the passage of a contrast medium through 
blood vessels for diagnostic purposes. A detailed discussion 
of these findings is discussed hereinbelow in Example 1 and 
is also available in an article entitled "Inhibition of prostag-
landin synthesis during polystyrene microsphere-induced 
pulmonary embolism in the rat,"American Journal of Physi-
ology-Lung Cellular & Molecular Physiology, 284:1072-
1081, 2003, which is incorporated by reference herein. 
[0040] Accordingly, a number ofuseful methods of detect-
ing and monitoring for pulmonary hypertension and related 
phenomena are proposed. In most cases, the method begins 
with the collection of one or more bodily fluids from the 
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mammalian subject. Examples of bodily fluids may include, 
but are limited to, whole blood, blood serum, plasma, urine, 
and expired breath condensate. In addition, the methods may 
begin with collection of expired breath in gaseous form. 
Methods and apparatuses suitable for collecting exhaled 
breath condensate have been described in several previous 
commonly-assigned patent applications, including provi-
sional U.S. Patent Application Ser. No. 60/434,916 filed 
Dec. 20, 2002 and entitled "DISPOSABLE HAND-HELD 
DEVICE FOR COLLECTION OF EXHALED BREATH 
CONDENSATE FOR ASSAY OF BIOMARKERS FOR 
THE DETECTION AND PROGNOSIS OF LUNG 
ISCHEMIA," and provisional U.S. Patent Application Ser. 
No. 60/447,581 filed Feb. 14, 2003 and entitled "DEVICE 
AND METHOD FOR COLLECTION OF EXHALED 
ALVEOLAR BREATH CONDENSATE," the entirety of 
each of which is incorporated herein by reference. 
[0041] Any of several markers for pulmonary hyperten-
sion, including free hemoglobin and its surrogates, and other 
phenomena may be measured in the collected bodily fluid or 
expired breath in order to effect diagnosis or the like. 
[0042] For example, in a first preferred method of the 
present invention, the presence of acute or chronic pulmo-
nary hypertension may be detected by measuring the con-
centration of haptoglobin, prehaptoglobin, free hemoglobin, 
and/or biliverdin and bilirubin in the collected bodily fluid. 
Similarly, the development of pulmonary hypertension in a 
mammalian subject may likewise be monitored by measur-
ing the concentration of haptoglobin, prehaptoglobin, free 
hemoglobin, and/or biliverdin and bilirubin in the collected 
bodily fluid. 
[0043] Monitoring a patient for the development of pul-
monary hypertension may be particularly useful in the case 
of suspected venous thromboembolism, sickle cell disease, 
fat embolism syndrome, tumor embolism syndrome, amni-
otic fluid embolism, pulmonary schistosomiasis, congestive 
heart failure, chronic obstructive pulmonary disease, pri-
mary pulmonary hypertension, Eisenmenger's syndrome, 
canine dirofilariasis, and the like. 
[0044] Once the presence of pulmonary hypertension has 
been detected, the response of a mammalian subject to 
treatment designed to reduce pulmonary arterial or vascular 
resistance may be assessed by collecting a bodily fluid and 
measuring the concentration of at least one of haptoglobin, 
prehaptoglobin, free hemoglobin, biliverdin, or bilirubin in 
the collected bodily fluid. Assessment may include assessing 
the response of the subject to inhalational drug therapy that 
is designed to reduce pulmonary arterial resistance and/or 
assessing the response of the subject to infused or ingested 
medications that are designed to reduce pulmonary vascular 
resistance. 
[0045] Measurement of the various markers may be 
accomplished in a variety of ways, including the use of an 
immunoglobulin-based assay format, an enzyme-linked 
immunoassay, fluorescent methods, colorimetric assays, 
bioassays and/or radioisotopic techniques. A person of ordi-
nary skill in the art would be familiar with each of these 
measurement methods. 
[0046] In a second preferred method of the present inven-
tion, the presence of acute or chronic pulmonary hyperten-
sion may be detected by determining the ratio of the con-
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centration of surrogate markers of free hemoglobin in 
expired breath. For example, pulmonary vasoconstriction 
due to intrapulmonary or free hemoglobin may be identified 
by determining the ratio of the concentration of expired 
carbon dioxide to expired oxygen. 
[0047] The ratio of C02 to 0 2 may be determined inde-
pendently or by using any of a variety of other techniques, 
including, but not limited to, determining the ratio as a 
function of expired volume, plotting the dynamic expired 
carbon dioxide content as a function of dynamic expired 
breath oxygen content with each breath cycle, plotting any 
point estimate of carbon dioxide from any portion of the 
expired breath cycle as a function of the oxygen content 
measured simultaneously, plotting the mathematical equa-
tion describing the line that defines the ratio of expired 
carbon dioxide to expired oxygen as a function of expired 
volume with each breath, and/or determining the area under 
the curve of the plot of the ratio of expired carbon dioxide 
to expired oxygen as a function of expired breath volume. 
[0048] It is a preferred aspect of this embodiment to 
determine the ratio of C02 to 0 2 in expired breath and use 
such ratio in combination with a measured concentration 
value of one or more of haptoglobin, prehaptoglobin, free 
hemoglobin, biliverdin and/or bilirubin in one or more 
bodily fluids to determine whether a mammalian subject has 
pulmonary hypertension. As discussed above, the concen-
tration of free hemoglobin and/or one or more of its surro-
gate markers may indicate hemolysis. Additionally, the ratio 
of C02 to 0 2 may likewise indicate pulmonary hypertension. 
Using these two measured values in conjunction with one 
another provides a stronger link between hemolysis and 
pulmonary hypertension and provides stronger evidence of 
pulmonary hypertension. 
[0049] The C02 to 0 2 ratio may likewise also be deter-
mined in conjunction with measurement of the exhaled free 
gas concentrations or partial pressures of carbon monoxide 
and nitric oxide. One of ordinary skill in the art would 
understand and be able to perform the above-listed methods. 
[0050] In addition to being used to detect the presence of 
pulmonary hypertension, surrogate markers of free hemo-
globin in expired breath may also be used to evaluate the 
effect of treatments designed to reduce free hemoglobin. 
This evaluation is performed using the same test methods 
described above for determining the ratio of the concentra-
tion of expired carbon dioxide to expired oxygen in expired 
breath. 
[0051] The method of the present invention may also be 
utilized to assess for intrapulmonary hemolysis and subse-
quent free hemoglobin release due to catheter or hydrojet 
fragmentation to treat intrapulmonary thrombosis. This may 
be accomplished by measuring the concentrations of expired 
nitric oxide and expired carbon monoxide or measuring the 
concentration of haptoglobin, prehaptoglobin, free hemo-
globin, biliverdin, or bilirubin in one or more bodily fluids 
collected from a mammalian subject as described herein 
above. 
[0052] It is also possible to identify the biological effect of 
free hemoglobin on the pulmonary vasculature by measuring 
the concentrations of expired gaseous nitric oxide and 
carbon monoxide or by measuring the concentrations of 
dissolved nitric oxide and carbon monoxide in expired 
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breath condensate. Either of these measurements may be 
carried out as an independent measurement or may be 
carried out in conjunction with measurement of one or more 
of the above-described markers (haptoglobin, prehaptoglo-
bin, free hemoglobin, biliverdin, or bilirubin) in a bodily 
fluid. 
EXAMPLES 
Example 1 
[0053] The effect of pulmonary embolism on the ratio of 
C02 to 0 2 in expired breath was measured in accordance 
with the present invention. 
[0054] In order to create and control the condition of 
pulmonary hypertension, polystyrene microsphere beads 
with a mean diameter of 24 µm were infused into a rat's 
venous circulation at a rate of 0.1 ml/min to induce fixed 
pulmonary obstruction. These beads were impervious and 
lodged into the rat's pulmonary arteries creating an occlu-
s10n. 
[0055] The concentration of expired C02 and 0 2 in rats 
having induced pulmonary embolism was measured accord-
ing to the following procedure. At 16 hours after pulmonary 
embolism induction, the rats were ventilated with a small-
animal, mechanical ventilator (model 2094; Kent Scientific, 
Lithfield, Conn.). To measure ventilation parameters, a gas 
flow transducer (model TSD 137C; Biopac Systems, Santa 
Barbara, Calif.) was attached to the inspiratory limb of the 
ventilator circuit. End-tidal C02 was measured by a side 
stream quantitative C02 capnometer (model C02 lOOA; 
Biopac Systems) attached to the expiratory limb. End-tidal 
0 2 was measured by a side stream paramagnetic oxygen 
sensor attached to the expiratory limb (model 0200A; 
Biopac Systems). After instrumentation, all rats were given 
succinylcholine to relax breathing efforts, allowing end-tidal 
C02 measurements to be obtained from fiat-topped, steady-
state expirograms, during controlled, constant mechanical 
ventilation and without interference from interposed spon-
taneous breathing efforts. 
[0056] End-tidal expired carbon dioxide ( etC02), end-
tidal expired oxygen ( et02), partial pressure of carbon 
dioxide in arterial blood (P c02) and partial pressure of 
oxygen in arterial blood (P 02) were all measured. Pulmo-
nary gas exchange was measured primarily by the alveolar 
deadspace volume, which was calculated using etC02 in the 
Severinghaus equation. It is known that an increase in 
alveolar deadspace volume correlates with an increase in 
pulmonary vascular resistance. 
[0057] Rats subjected to pulmonary embolism demon-
strated a statistically significant decrease in peak partial 
pressure of carbon dioxide measured at end-tidal respiration 
and an increase in the nadir end-tidal partial pressure of 
oxygen measurement, which was coincident with increased 
alveolar deadspace volume and a significantly increased 
difference between the end-tidal partial pressure of oxygen 
and the arterial partial pressure of oxygen. Accordingly, as 
was hypothesized, in rats subjected to pulmonary embolism, 
the ratio of the partial pressure of carbon dioxide over the 
partial pressure of oxygen decreased in proportion to the 
alveolar deadspace volume increase. 
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Example 2 
[0058] The effect of pulmonary embolism on the concen-
tration of haptoglobin in blood was measured in accordance 
with the present invention. 
[0059] Blood specimens were obtained from patients with 
pulmonary embolism who underwent an echocardiography-
Doppler study. Each patient's right ventricular pressure was 
estimated by incorporating the measured velocity of the 
"regurgitant jet" across the tricuspid valve and an assumed 
central venous pressure into a modification of the Bernoulli 
equation. 
[0060] Each patient was categorized into one of three right 
ventricular pressure (RVSP) groups: Normal (no regurgitant 
jet or RVSP<20 mm Hg), Mild (RVSP 30-40 mm Hg), 
Moderate (RVSP 45-55 mm Hg) and High (RVSP>55 mm 
Hg). 
[0061] Haptoglobin concentrations were measured using 
an ELISA assay, constructed with the use of a commercially 
available antibody against haptoglobin. One of ordinary skill 
in the art would understand how to perform the ELISA 
assay. For reference, haptoglobin was measured in the blood 
of healthy persons free of pulmonary embolism. 
[0062] FIG. 2 is a graphical representation of the results 
of the ELISA assay analysis. The analysis indicated that 
patients having pulmonary embolism, but also having nor-
mal right ventricular pressure, had elevated haptoglobin 
concentrations relative to healthy patients (i.e., normal 
approximately 800-1200 ug/mL, versus > 1500 ug/mL for 
patients with pulmonary embolism and normal pressures). 
This result suggests an "induction" effect that is consistent 
with the acute phase reactant nature of haptoglobin in 
response to the inflammatory effect of venous thrombosis. 
[0063] However, as the right ventricular pressure 
increased, the haptoglobin concentration decreased com-
pared to normal, and then serum haptoglobin concentrations 
decreased to subnormal concentrations (i.e., <800 ug/mL) in 
approximately 75% of patients with severe pulmonary 
hypertension. Accordingly, it can be seen that patients with 
pulmonary embolism with elevated haptoglobin concentra-
tions are less likely to have associated pulmonary hyperten-
sion, whereas patients with pulmonary embolism and nor-
mal or decreased serum haptoglobin concentrations (i.e., 
below 1000 ug/mL) are likely to have associated pulmonary 
hypertension. 
Example 3 
[0064] The effect of pulmonary embolism on the ratio of 
C02 to 0 2 in expired breath was measured in accordance 
with the present invention. 
[0065] A device as described in the '918 patent was used 
to measure the expired ratio of C02 to 0 2 in 178 patients 
evaluated for possible pulmonary embolism. In addition, the 
same 178 patients underwent standardized evaluation tech-
niques for pulmonary embolism as a means to verify results 
obtained using the breathing device. 
[0066] The patients were asked to use a particular breath-
ing technique when using the breathing device. Specifically, 
the patients breathed room air for at least two minutes. Then, 
while in semi-Fowler's position, and wearing nose clips, 
patients breathed into a duckbill-shaped mouthpiece in air-
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tight connection with the airflow transducer. A research 
assistant provided help to the patient as needed. Patients 
delivered a sharp, rapid, deep exhalation to a maximum 
endpoint, starting from a midpoint of tidal breathing (i.e., 
not delivered after a sigh inspiration) followed by a few 
normal breaths, and then a 30 second period of tidal breath-
ing. The term "tidal breathing," as used in the present 
invention refers to a person's normal breathing while at rest 
and is in contrast to deep exhalation. This sequence was 
repeated twice more, yielding three deep exhalations and 
three 30-second samples of tidal breathing. 
[0067] The same patients then underwent standardized 
evaluations for pulmonary embolism, including a D-dimer 
screening step in many cases, and then contrast-enhanced 
computerized tomography angiography of the chest and 
indirect venography, which was interpreted by board-certi-
fied body radiologists who were unaware of study results. 
[0068] Table 1 shows the mean breathing device measure-
ments from three deep exhalations for all 178 patients. P co2 
maximum is the maximum partial pressure of C02 in a given 
exhalation, P 02 minimum is the minimum partial pressure of 
0 2 in a given exhalation and P co2 max/P 02 min is the ratio 
of the two previous numbers. PE+ indicates that the diag-
nosis was pulmonary hypertension and PE- indicates that 
the diagnosis was no pulmonary hypertension. 
TABLE 1 
Expired breath data obtained from three deep exhalations 
Deep exhalation 
First Second Third 
Parameter Diagnosis mean* mean mean 
Breath volume (L) PE+ 1.13 1.14 1.13 
PE- 1.06 0.99 1.01 
P co2 maximum PE+ 36.9 38.3 37.9 
PE- 45.3 45.2 44.5 
P02 minimum PE+ 108 106 107 
PE- 98 99 100 
P co2 max/P 02 min PE+ 0.36 0.38 0.37 
PE- 0.48 0.48 0.47 
*Mean of one breath from 154 PE- patients and 24 PE+ patients 
[0069] The diagnostic utility of expired P co2 and P 02 was 
first investigated by plotting P co2 versus P 02. FIGS. 3 and 
4 show the plot of P co2 versus P 02 for 178 patients using the 
mean values of the first two deep exhaled breaths and the 
mean end-tidal P c02 and P 02 obtained during the first 
minute of tidal breathing respectively. The dark curved lines 
represent the best-fit discriminate line that separates patients 
with pulmonary embolism (PE+) from those without pul-
monary embolism (PE). Patients with PE+ tend to fall below 
the line, and patients without PE tend to be above the line. 
Each plot was divided into quadrants (straight lines with 
arrowheads) to separate out the patients based on probability 
as predicted by their location on the plot. Comparison of the 
lower right-hand quadrants suggests that the end-tidal P co2 
and P02 data (FIG. 4) had a slight advantage over the 
deep-expired P co2 and P 02 data (FIG. 3) as a rule in 
instrument. 
[0070] Twenty-four (13%) of these 178 patients were 
ultimately diagnosed with pulmonary embolism. Some of 
these patients, both with pulmonary embolism and without 
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pulmonary embolism, underwent echocardiography-Dop-
pler examination, and were categorized as having no pul-
monary hypertension versus moderate or severe pulmonary 
hypertension using the RVSP cutoff values described here-
inabove in Example 2. It was found that patients with 
pulmonary embolism and moderate or severe pulmonary 
hypertension generally had a ratio of C02 to 0 2 that was 
<0.30 whereas patients with moderate or severe pulmonary 
hypertension and no pulmonary embolism generally had 
ratio of C02 to 0 2 of >0.30. The implication is that pulmo-
nary hypertension as a consequence of pulmonary embolism 
causes more severe reduction in the ratio of C02 to 0 2 than 
does pulmonary hypertension that is caused by other prob-
lems. When used in combination with pretest probability, the 
breathing device produced a relatively high specificity while 
retaining reasonable sensitivity. 
[0071] Based on the foregoing information, it is readily 
understood by those persons skilled in the art that the present 
invention is susceptible of broad utility and application. 
Many embodiments and adaptations of the present invention 
other than those specifically described herein, as well as 
many variations, modifications, and equivalent arrange-
ments, will be apparent from or reasonably suggested by the 
present invention and the foregoing descriptions thereof, 
without departing from the substance or scope of the present 
invention. Accordingly, while the present invention has been 
described herein in detail in relation to its preferred embodi-
ment, it is to be understood that this disclosure is only 
illustrative and exemplary of the present invention and is 
made merely for the purpose of providing a full and enabling 
disclosure of the invention. The foregoing disclosure is not 
intended to be construed to limit the present invention or 
otherwise exclude any such other embodiments, adaptations, 
variations, modifications or equivalent arrangements; the 
present invention being limited only by the claims appended 
hereto and the equivalents thereof. Although specific terms 
are employed herein, they are used in a generic and descrip-
tive sense only and not for the purpose of limitation. 
What is claimed is: 
1. A method of detecting and monitoring the presence of 
acute or chronic pulmonary hypertension in a mammalian 
subject, comprising: 
(a) collecting a bodily fluid; 
(b) measuring the concentration of free hemoglobin in the 
bodily fluid; and 
(c) determining whether the concentration of free hemo-
globin in the bodily fluid indicates the presence of 
pulmonary hypertension. 
2. The method of claim 1, further comprising collecting 
expired breath, measuring the concentration of carbon diox-
ide and oxygen in the expired breath, calculating a ratio of 
the concentration of carbon dioxide to the concentration of 
oxygen in the expired breath and determining whether the 
ratio of carbon dioxide to oxygen in the expired breath in 
combination with the concentration of free hemoglobin in 
the first bodily fluid indicates the presence of pulmonary 
hypertension. 
3. The method of claim 1, wherein the bodily fluid is a first 
bodily fluid, wherein the method further comprises collect-
ing a second bodily fluid, measuring the concentration of 
dissolved nitric oxide and carbon monoxide in the second 
bodily fluid and determining whether the concentration of 
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nitric oxide and carbon monoxide in the second bodily fluid 
in combination with the concentration of free hemoglobin in 
the first bodily fluid indicates the presence of pulmonary 
hypertension. 
4. The method of claim 3, wherein the first bodily fluid is 
selected from a group consisting of whole blood, blood 
serum and plasma, and the second bodily fluid is expired 
breath condensate. 
5. A method of detecting and monitoring the presence of 
acute or chronic pulmonary hypertension in a mammalian 
subject, comprising: 
(a) collecting a bodily fluid; 
(b) measuring the concentration of an at least one surro-
gate marker of free hemoglobin in the bodily fluid; and 
( c) determining whether the concentration of the surrogate 
marker of free hemoglobin in the bodily fluid indicates 
the presence of pulmonary hypertension. 
6. The method of claim 5, further comprising collecting 
expired breath, measuring the concentration of carbon diox-
ide and oxygen in the expired breath, calculating a ratio of 
the concentration of carbon dioxide to the concentration of 
oxygen in the expired breath and determining whether the 
ratio of carbon dioxide to oxygen in the expired breath in 
combination with the concentration of an at least one 
surrogate marker of free hemoglobin in the bodily fluid 
indicates the presence of pulmonary hypertension. 
7. The method of claim 5, wherein the at least one 
surrogate marker of free hemoglobin in the bodily fluid 
includes haptoglobin. 
8. The method of claim 7, wherein the bodily fluid is a first 
bodily fluid, wherein the method further comprises collect-
ing a second bodily fluid, measuring the concentration of 
dissolved nitric oxide and carbon monoxide in the second 
bodily fluid and determining whether the concentration of 
dissolved nitric oxide and carbon monoxide in the second 
bodily fluid in combination with the concentration of hap-
toglobin in the first bodily fluid indicates the presence of 
pulmonary hypertension. 
9. The method of claim 8, wherein the first bodily fluid is 
selected from a group consisting of whole blood, blood 
serum and plasma and the second bodily fluid is expired 
breath condensate. 
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10. The method of claim 7, wherein a haptoglobin con-
centration of less than or equal to 1000 ug/mL indicates the 
presence of pulmonary hypertension. 
11. The method of claim 5, wherein the at least one 
surrogate marker of free hemoglobin in the bodily fluid 
includes prehaptoglobin. 
12. The method of claim 5, wherein the at least one 
surrogate marker of free hemoglobin in the bodily fluid 
includes biliverdin. 
13. The method of claim 5, wherein the at least one 
surrogate marker of free hemoglobin in the bodily fluid 
includes bilirubin. 
14. The method of claim 5, wherein the at least one 
surrogate marker of free hemoglobin in the bodily fluid 
includes dissolved nitric oxide and carbon monoxide. 
15. A method of detecting and monitoring the presence of 
acute or chronic pulmonary hypertension in a mammalian 
subject, comprising: 
(a) collecting expired breath; 
(b) measuring the concentration of an at least one surro-
gate marker of free hemoglobin in the expired breath; 
and 
( c) determining whether the concentration indicates the 
presence of pulmonary hypertension. 
16. The method of claim 15, wherein the at least one 
surrogate marker of free hemoglobin includes carbon diox-
ide and oxygen. 
17. The method of claim 16, further comprising deter-
mining a ratio of the concentration of carbon dioxide to the 
concentration of oxygen. 
18. The method of claim 17, wherein a ratio of carbon 
dioxide to oxygen of less than 0.30 indicates the presence of 
pulmonary hypertension. 
19. The method of claim 15, wherein the at least one 
surrogate marker of free hemoglobin includes expired nitric 
oxide and carbon monoxide content. 
* * * * * 
